HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preclinical anticancer activity of DNA-based cleavage molecules.

Abstract
Deoxyribozymes (DNAzymes) are DNA residue-based molecules capable of specific cleavage of complementary mRNA. As such, they are more stable counterparts for the earlier discovered ribozymes. A handful of studies have shown the potential of DNAzymes against cancer both in cell culture and importantly in vivo models. This relatively new molecular entity may progress to clinical trials provided that more extensive testing is carried out at the preclinical stage. While a significant amount of work has gone into chemically stabilizing the molecule, delivery is one area that needs particular attention.
AuthorsCrispin R Dass
JournalDrug development and industrial pharmacy (Drug Dev Ind Pharm) Vol. 32 Issue 1 Pg. 1-5 (Jan 2006) ISSN: 0363-9045 [Print] England
PMID16455599 (Publication Type: Journal Article, Review)
Chemical References
  • DNA enzyme ED5
  • DNA, Catalytic
  • DNA, Single-Stranded
  • Twist-Related Protein 1
  • Vascular Endothelial Growth Factor Receptor-2
  • Ornithine Decarboxylase
Topics
  • Animals
  • Cells, Cultured
  • DNA, Catalytic (pharmacology, therapeutic use)
  • DNA, Single-Stranded (pharmacology, therapeutic use)
  • Genes, jun
  • Humans
  • Neoplasms (therapy)
  • Ornithine Decarboxylase (genetics)
  • Twist-Related Protein 1 (genetics)
  • Vascular Endothelial Growth Factor Receptor-2 (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: